Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
A new simulation study indicates that women with stage II breast cancer who have a high risk of the cancer remaining in their axillary (underarm) lymph nodes after treatment, called residual nodal disease, may benefit from having these lymph nodes removed in a procedure called an axillary lymph node dissection. Women who have more cancerous lymph nodes in the underarm generally have a higher risk of residual nodal disease. Cancer in this area is found through a sentinel lymph node biopsy. A sentinel lymph node biopsy is the removal of one or a few lymph nodes in the underarm to look for cancer cells. If cancer cells are found, additional treatment may be needed.
In a recent study, researchers found that a new device called MarginProbe helps make sure enough tissue is removed during a lumpectomy. A lumpectomy is the removal of the tumor and some of the surrounding tissue, called a margin, during an operation. Currently, surgeons often have to wait one or two weeks to find out if the tissue around the tumor that was removed during surgery contains cancer cells. Because of this, up to 40% of women who have had a lumpectomy need to have more surgeries to remove this additional cancerous tissue.
Using a specialized 21-gene test of a breast tumor’s genes, researchers found that the result, called a Recurrence Score (RS), predicted the prognosis (chance of recovery) for patients with estrogen-receptor positive breast cancer that has spread to the axillary (underarm) lymph nodes. Previous studies have shown that these 21 genes help predict the risk of recurrence (cancer that comes back after treatment) and the risk of death from cancer for women with breast cancer that has not spread to the axillary lymph nodes.
In a recent review of previous studies, researchers found that bone scans, liver ultrasounds, and chest x-rays are not good tests for finding cancer that has spread for women newly diagnosed with breast cancer who have no symptoms of the disease. Bone scans, liver ultrasounds, and chest x-rays are called imaging tests and are used to create pictures of the inside of the body. These tests are often used to find possible metastases (areas where cancer has spread), but there is no standard procedure or solid evidence that they are beneficial in this situation.